

CytomX Therapeutics, Inc. Logo

CytomX Announces Conference Call and Webcast to Review PROCLAIM-072 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

June 1, 2018

SOUTH SAN FRANCISCO, Calif., June 01, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced that it will host a conference call and live webcast on Monday, June 4th at 5:00 p.m. CT/ 6:00 p.m. ET to discuss presentations of preliminary clinical results from PROCLAIM-072, an ongoing Phase 1/2 trial evaluating CX-072, a Probody therapeutic targeting PD-L1, at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO). Conference call and webcast details are as follows:

Date and Time:

- Monday, June 4, 2018
- 5:00 p.m. Central Time/ 6:00 p.m. Eastern Time

Audio Conference Call:

- U.S. Toll Free Dial-in Number: (877) 809-6037
- International Dial-in Number: (615) 247-0221
- Conference ID: 4294667

Live Webcast:

- Access the Events and Presentations Section of CytomX's Investor Relations section at <http://ir.cytomx.com/events-and-presentations>
- Access the website 15 minutes prior to the start of the call to download and install any necessary audio software with slides

Replay:

- A replay of the webcast will be archived and available on CytomX's website for three months following the event.

About CytomX Therapeutics

CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company's pipeline includes cancer immunotherapies against clinically-validated potential targets, such as CX-072, a PD-L1-targeting Probody therapeutic wholly-owned by CytomX, BMS-986249, a CTLA-4-targeting Probody therapeutic partnered with Bristol Myers Squibb, CX-188, a PD-1-targeting Probody therapeutic wholly-owned by CytomX, and first-in-class Probody drug conjugates against high potential targets, such as CX-2009, a CD166-targeting Probody drug conjugate wholly-owned by CytomX and CX-2029, a CD71-targeting Probody drug conjugate partnered with AbbVie, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.

CytomX Therapeutics

Investors:

Christopher Keenan
VP, Investor Relations and Corporate Communications
ckeenan@cytomx.com
650-383-0823

Media:

Spectrum
Christine Quern
cquern@spectrumsience.com
202-587-2588



Source: CytomX Therapeutics Inc.